Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety, pharmacokinetics, pharmacodynamics, and efficacy of RO7268489 as an add-on therapy to ocrelizumab in adults with progressive multiple sclerosis PMS. This phase II, multi-center, double-blind, placebo-controlled study aims to understand how RO7268489 affects disability progression and other clinical measures in PMS patients receiving ocrelizumab. The study is sponsored by Hoffmann-La Roche and involves randomized parallel groups. Participants will receive either one of three doses of RO7268489 or a matching placebo, each combined with ocrelizumab according to a predefined dosing schedule. After the double-blind treatment period, eligible participants may continue to receive open-label RO7268489 in an extension phase. The interventions involve drug administration per schedule alongside ongoing ocrelizumab treatment. During the study, participants will be monitored for up to approximately 110 weeks for disability progression and cognitive function using standardized tests and assessments. Researchers will measure brain volume changes, plasma levels of 2-arachidonoylglycerol and the study drug, and track adverse events including treatment discontinuations and suicidal ideation up to 5 years. This comprehensive monitoring includes clinical evaluations, imaging, and laboratory tests to assess safety and efficacy over the study and follow-up periods.